Legalization of CBD Boosts Double-digit Sales Growth for NLC

Market by 2FIRSTS.ai

Sep.04.2023

Legalization of CBD Boosts Double-digit Sales Growth for NLC

Legalization of CBD has helped Newfoundland and Labrador Liquor Corporation (NLC) achieve double-digit sales growth, reports suggest.

According to reports from foreign media, the legalization of cannabidiol (CBD) has aided the Newfoundland and Labrador Liquor Corporation (NLC) in achieving double-digit sales growth.

Bruce Keating, CEO of NLC, has stated that despite facing more challenging market conditions in the alcohol industry, cannabis sales are showing a growth trend.

Compared to the same period last year, first-quarter sales of marijuana have increased by 25.6%.

He pointed out that part of the reason can be traced back to the decision to legalize marijuana smoking accessories last autumn.

At the same time, Kiting also pointed out that high inflation is one of the reasons challenging the alcoholic beverage industry market due to its impact on disposable income.

References:

[1] Vape Products Drive Double-Digit Growth in Cannabis Sales for NLC

#E-liquids #Market #Africa #South Africa #CBD #CBD e-liquids

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

China Tobacco Regulation Shift：Policy Updates and Market Impact

China Tobacco Regulation Shift：Policy Updates and Market Impact

PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries

PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries

At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.

FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty

FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty

FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.

Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework

Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework

At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.

FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability

FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability

During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.

PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries

PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries

During FDA’s Feb 10 PMTA roundtable (manufacturing controls panel), small ENDS manufacturers warned that uncertainty in manufacturing expectations creates existential financial risk. FDA officials reiterated review flexibility is constrained by statutory and scientific boundaries. The panel debated testing standards, documentation requirements, open-system responsibility, supply chain changes, and software updates—highlighting unresolved PMTA challenges for small manufacturers.

Related Topics

Related Read

PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries

PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries

FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty

FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty

Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework

Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework

FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability

FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability

PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries

PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries